NOVADAQ to Report Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
February 15 2017 - 4:05PM
NOVADAQ Technologies Inc (NASDAQ:NVDQ) (TSX:NDQ), the leading
provider of proven comprehensive fluorescence imaging solutions
that improve clinical outcomes and reduce healthcare costs in
minimally invasive and open surgeries, today announced that it will
release financial results for the fourth quarter and full year 2016
after the close of trading on Tuesday, February 28, 2017. The
Company’s management team will host a corresponding conference call
beginning at 4:30 p.m. ET.
Investors interested in listening to the conference
call may do so by dialing 877-407-8031 (within Canada and the U.S.)
or 201-689-8031 (outside Canada and the U.S.). A live and
archived webcast of the event will be available on the “Investor
Relations” section of the Company’s website at:
www.novadaq.com.
A replay of the call will be available for 48 hours
by calling 877-481-4010 (within Canada and the U.S.) or
919-882-2331 (outside Canada and the U.S.), using Conference ID:
10229.
About NOVADAQ Technologies
Inc. NOVADAQ’s global mission is to enable physicians
with point-of-care imaging solutions that provide real-time
clinically significant and actionable information to improve care
quality and lower healthcare costs. Using NOVADAQ’s SPY
fluorescence imaging technology, physicians can personalize therapy
and achieve optimal results through the precise visualization of
blood flow in vessels, micro-vessels, tissue perfusion and critical
anatomical structures during the course of treatment. SPY
technology enables the delivery of personalized therapies and the
achievement of the optimal results for each individual patient.
More than 230 peer-reviewed publications demonstrate that the use
of SPY technology will reduce post-procedure complication rates and
the cost of care for a broad variety of surgical treatments for
cancer, cardiovascular diseases and other conditions, helping to
ensure that patients benefit from the very best possible treatment
and outcome.
SPY Imaging Systems are U.S. Food and Drug
Administration 510(k) cleared, Health Canada licensed, CE Marked
and registered worldwide for use in multiple surgical specialties
and medical applications. The endoscopic version of SPY technology,
known as PINPOINT, combines the fluorescence imaging capabilities
of SPY with the high definition visible light visualization to
establish a new standard in the quality and performance of
minimally invasive surgery. NOVADAQ’s LUNA System is used to
visualize blood flow and tissue perfusion while treating patients
with atherosclerotic cardiovascular disease that impairs blood flow
to the extremities and increases the risk for the development of
complications such as acute and chronic non-healing wounds and limb
loss. NOVADAQ is the exclusive worldwide distributor of LifeNet
Health’s DermACELL acellular tissue products for wound and breast
reconstruction surgery
NOVADAQ, SPY, PINPOINT, LUNA and the illumination
square design are registered trademarks of NOVADAQ Technologies,
Inc. DermACELL is a registered trademark of LifeNet Health,
Inc.
For more information, please contact:
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@novadaq.com
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novadaq Technologies (NASDAQ:NVDQ)
Historical Stock Chart
From Aug 2023 to Aug 2024